newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Devdiscourse
Health innovations and economic shifts are making waves globally.
Mirum Pharmaceuticals' rare liver disease drug achieved a key milestone in a mid-stage clinical study.
KEY POINTS
Swiss biotechs saw a 38% increase in private investment compared to 2024 amid tough markets.
GMR Solutions targets a $5 billion valuation with a planned IPO in the United States.
A hantavirus outbreak on a cruise ship led to three passenger deaths.
Health innovations and economic shifts are making waves globally. Mirum Pharmaceuticals has reached a significant milestone with its rare liver disease drug in a mid-stage study. Meanwhile, Swiss biotechs are benefiting from a pivot towards private funding amid challenging capital markets, revealing a 38% increase in private investment compared to 2024.
In investment news, multiple pharmaceutical and biotech companies are preparing for substantial IPOs. Emergency medical services provider GMR Solutions eyes a $5 billion valuation in the U.S., while China's Impact Therapeutics and Boston-based Odyssey Therapeutics are also launching IPOs in Hong Kong and the U.S. respectively, signaling strong investor interest.
On a critical note, health alerts have arisen with a hantavirus outbreak on a cruise ship resulting in three deaths. Additionally, legal tussles over mail-order access to mifepristone continue in the U.S., reflecting the ongoing debates surrounding reproductive health policies.
(With inputs from agencies.)